AbbVie Inc (ABBV)

87.03
0.66 0.76
NYSE : Health Care
Prev Close 86.37
Open 86.40
Day Low/High 86.25 / 87.40
52 Wk Low/High 55.06 / 89.69
Volume 2.46M
Avg Volume 5.54M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 136.01B
EPS 3.60
P/E Ratio 16.22
Div & Yield 2.56 (3.00%)

Latest News

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Don't be distracted and start buying high and selling low, says Jim Cramer. A good example? Don't trade Apple, own it.

AbbVie Is Likely to Correct: Book Some Profits

AbbVie Is Likely to Correct: Book Some Profits

ABBV has gone 'vertical' on the daily chart.

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

AbbVie Submits New Drug Application To U.S. FDA For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

AbbVie Submits New Drug Application To U.S. FDA For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse

AbbVie Becomes #164 Most Shorted S&P 500 Component, Replacing Moody's Corp.

The most recent short interest data has been released for the 08/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Hedge fund managers are out with their top stock picks. So who made the list?

What SOX Says About Oversold Rallies

Expect the market to come down again.

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Evercore ISI analyst Josh Schimmer is bullish on biotech.

Activision Blizzard, EPR Properties, AbbVie: 'Mad Money' Lightning Round

Activision Blizzard, EPR Properties, AbbVie: 'Mad Money' Lightning Round

Jim Cramer is bullish on EPR Properties, Activision Blizzard, AbbVie, and ON Semiconductor.

How Much Cash Do You Have on You?: Cramer's 'Mad Money' Recap (Monday 8/14/17)

How Much Cash Do You Have on You?: Cramer's 'Mad Money' Recap (Monday 8/14/17)

Cramer says this is not the end of the selloff. That's why you should be mentally and financially ready for panic moves -- and opportunities.

AbbVie Receives U.S. FDA Approval Of MAVYRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT 1-6) In As Short As 8 Weeks

AbbVie Receives U.S. FDA Approval Of MAVYRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT 1-6) In As Short As 8 Weeks

- MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- MAVIRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

What differentiated traders who were injured yesterday from those able to whether a sudden storm? Diversification.

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

U.S. stock futures fall as earnings from Amazon.com disappoint.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

AbbVie Receives CHMP Positive Opinion For HUMIRA® (adalimumab) For The Treatment Of Pediatric Patients With Chronic Non-infectious Anterior Uveitis

AbbVie Receives CHMP Positive Opinion For HUMIRA® (adalimumab) For The Treatment Of Pediatric Patients With Chronic Non-infectious Anterior Uveitis

- If approved, HUMIRA® will be the first biologic treatment option in the European Union for pediatric patients with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy

AbbVie Reaches All-Time Highs

AbbVie Reaches All-Time Highs

Today's breakout could carry the stock sharply higher.

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Remarkable data was released from Vertex's triple regiment combination trials.

All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'

All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'

Tech companies aren't the only ones seeing their shares rise this year.

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

TheStreet Quant Rating: A (Buy)